SWOG clinical trial number
MM1OA-S04
A Phase 2 trial of ASTX727 with standard duration versus shorter duration of venetoclax in genomically heterogenous AML among adults aged 60 or older and less fit for intensive therapy: a myeloMATCH substudy.
Open
Phase
Accrual
1%
Abbreviated Title
Comparing Standard vs Shorter Duration Venetoclax in Older and Less Fit Adults
Activated
07/22/2026
Participants
ALLIANCE, ECOG-ACRIN, NRG
Research committees
myeloMATCH
Treatment
Venetoclax
ASTX727
Other Clinical Trials
SWOG Clinical Trial Number
MM1OA-S04
A Phase 2 trial of ASTX727 with standard duration versus shorter duration of venetoclax in genomically heterogenous AML among adults aged 60 or older and less fit for intensive therapy: a myeloMATCH substudy.
Research Committee(s)
myeloMATCH
Activated
07/22/2026
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
MM1OA-S03
A Randomized Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML: A myeloMATCH Substudy
Research Committee(s)
myeloMATCH
Leukemia
Activated
04/01/2025
Accrual
29%
Open
Phase
SWOG Clinical Trial Number
MYELOMATCH
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH trials
Research Committee(s)
myeloMATCH
Leukemia
Activated
05/16/2024
Open
Phase